These were the biggest pharmaceutical deals in early 2022
There were 256 deals recorded involving top pharmaceutical companies in the three months to April with a number of high profile contract service agreement, licensing…
Patent Analytics
Trends in IP Protection— Pharma (Last 20 Years)
Heavy IP Protected Regions — Pharma (Last 20 Years)
Top Players Protecting their IP — Pharma (Last 20 Years)
Top Themes Protected by IP - Pharma (Last 20 Years)
All markets data shared in the dashboard is copyright of GlobalData PLC and is subject to the GlobalData Terms & Conditions. Content in the dashboard should not be viewed as a recommendation and should not be relied upon to make investment decisions. We make every effort to ensure our content is accurate and to correct mistakes as soon as possible. If you spot an error please email editorialenquiries@globaldata.com. Further information about our editorial standards and complaints procedure is available here. GlobalData is not responsible for the use of any content outside the scope of the GlobalData Terms & Conditions.
Latest News
View More
Pfizer and BioNTech amend Covid-19 vaccine supply deal with EC
Pfizer and BioNTech have amended the supply agreement with the European Commission (EC) to rephase the delivery schedules of their Covid-19 vaccine. The Pfizer-BioNTech COVID-19…
FDA grants Orphan Drug Designation to Editas’ beta thalassemia therapy
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Editas Medicine’s experimental gene editing therapy, EDIT-301,…
Covid-19 patent lawsuits: Will vaccine producers have to pay the bill?
In a new chapter with emerging legal dimensions for the Covid-19 vaccine success story, last week Moderna submitted a filing…
Taiho signs deal to acquire Cullinan Pearl for up to $405m
Taiho Pharmaceutical has signed an agreement under which the company will acquire Cullinan Oncology subsidiary, Cullinan Pearl, in a deal valued at…
BridgeBio and BMS partner to develop BBP-398 for cancer
BridgeBio Pharma and Bristol Myers Squibb (BMS) have entered an exclusive licence agreement for developing and marketing BBP-398 in oncology. An inhibitor…
Company A-Z
View More
SIRION Biotech
Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development
